Artemisinin Combination Therapy Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Artemisinin Combination Therapy Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The artemisinin combination therapy market is expected to register a CAGR of 8.31% over the forecast period, 2022-2027.

The COVID-19 pandemic had a significant impact on market growth. According to the article published in July 2020 titled, "Identifying and combating the impacts of COVID-19 on malaria", children and pregnant women were bearing a disproportionate burden of excess malaria mortality arising from COVID-19-related disruption of health systems and malaria control programs, particularly in sub-Saharan Africa. This was primarily because the COVID-19 pandemic was disrupting malaria diagnosis as both these diseases share some symptoms. It is because of these factors that the artemisinin combination therapy market was expected to be affected during the COVID-19 pandemic.

Artemisinin combination therapy (ACT) is used for the treatment of Plasmodium falciparum malaria. This market has been growing in recent years due to the high prevalence of malaria, especially in developing and under-developing countries.

According to the World Malaria Report July 2020 published by the World Health Organization (WHO), there were an estimated 229 million cases of malaria worldwide. It also stated that the estimated number of malaria deaths stood at 409,000. Thus, the high prevalence of malaria in certain regions is expected to boost demand for malaria diagnostic tools boosting the market growth.

Additionally, awareness programs and other government initiatives are other factors that propel market growth. For instance, in July 2022, the Ministry of Health and Family Welfare of India launched Jan Abhiyaans with log bhaagidari (people’s participation) to enthuse and engage citizens and communities to ensure that their homes, premises, and neighborhoods are free of mosquitoes. Thus, such initiatives are likely to increase market growth.

However, side-effects of anti-malarial drugs and the presence of counterfeit and substandard drugs are restraining the growth of this market.

Key Market TrendsArtemether-Lumefantrine Segment is Expected to Dominate the Market Over the Forecast Period

Artemether-Lumefantrine is a combination of the two medications artemether and lumefantrine. It is used to treat malaria caused by Plasmodium falciparum which is not treatable with chloroquine. They were both developed in China. It is one of the drugs on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.

The World Health Organization recommends that uncomplicated Plasmodium falciparum malaria should be treated with artemisinin-lumefantrine combination therapy. As per the study published in May 2021, titled ''Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Ethiopia: a systematic review and meta-analysis", artemether-lumefantrine therapy is efficacious and safe in treating uncomplicated falciparum malaria in Ethiopia.

As per the article published by the World Health Organization in April 2022, titled ''Over 1 million African children protected by first malaria vaccine", several other antimalarial medicines with new modes of action are being developed for the treatment of uncomplicated and severe malaria. Ganaplacide-Lumefantrine, currently in Phase II clinical trial, is the first non-artemisinin combination therapy and could be an asset in the fight against emerging drug-resistant malaria in Africa.

As this combination is used as the first-line drug for malaria in most countries, it is expected to cover a large share of the global artemisinin combination therapy market.

Middle East and Africa is Expected to Show a High Growth Over the Forecast Period

The Middle East and Africa region are expected to retain dominance in the market share over the forecast period, due to the rising investments by the developed countries, larger patient populations, coupled with the rising focus of the World Health Organization (WHO) to reduce the mortality rate of malaria in the African countries.

According to the data published by the World Health Organization, in 2021, Sub-Saharan Africa likely continues to endure the burden of malaria, accounting for approximately 95% of all cases and 96% of all deaths. According to the data published by the World Health Organization, in 2021, the evidence of the occurrence of mutations linked to partial artemisinin, which is the first-line treatment for uncomplicated P. falciparum malaria, resistance found in Rwanda in Africa. P. falciparum is the most prevalent malarial parasite in the region, accounting for an estimated 99% of all cases in Africa according to the WHO. Also, as per the same source children under the age of 5 years are the most vulnerable group affected by malaria since they accounted for 67% (274 000) of all malaria deaths worldwide. These facts are indicative of the rising prevalence of malaria diagnostics in the Middle East and Africa. Thus, the increasing cases of malaria in the region require effective treatment which is further expected to boost the growth of the market in the region over the forecast period.

Moreover, in August 2022, President Muhammadu Buhari in Abuja inaugurated Nigeria End Malaria Council (NEMC), projecting that the successful implementation of the council’s agenda and savings from the estimated economic burden of the disease would save Nigeria about N687 billion in 2022 and N2 trillion by 2030. Such initiatives taken by the Government in the region are expected to boost the growth of the market over the forecast period.

Owing to these factors, the Middle East and Africa region is expected to have one of the largest shares in the artemisinin combination therapy market.

Competitive Landscape

The artemisinin combination therapy market is fragmented and competitive and consists of several major players. The majority of the artemisinin combination therapy drugs are being manufactured by the global key players. Market leaders with more funds for research and better distribution system have established their position in the market. Some of the global players are based in developed countries like the United States, the United Kingdom, France, Germany, and Japan. Some of the companies currently dominating the market are Cipla Inc., PLC, Novartis AG, Sanofi S.A., KPC Pharmaceuticals, and Shanghai Fosun Pharmaceutical Co., Ltd. among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.